CN118086394A - Pig adipose tissue development tracing system and application - Google Patents
Pig adipose tissue development tracing system and application Download PDFInfo
- Publication number
- CN118086394A CN118086394A CN202410497313.6A CN202410497313A CN118086394A CN 118086394 A CN118086394 A CN 118086394A CN 202410497313 A CN202410497313 A CN 202410497313A CN 118086394 A CN118086394 A CN 118086394A
- Authority
- CN
- China
- Prior art keywords
- pig
- sequence
- vector
- seq
- adipose tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000011759 adipose tissue development Effects 0.000 title claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 58
- 239000013598 vector Substances 0.000 claims abstract description 44
- 239000000700 radioactive tracer Substances 0.000 claims abstract description 28
- 230000006698 induction Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000011161 development Methods 0.000 claims abstract description 11
- 230000018109 developmental process Effects 0.000 claims abstract description 11
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims description 32
- 125000003729 nucleotide group Chemical group 0.000 claims description 32
- 108091033409 CRISPR Proteins 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 13
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 claims description 12
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 claims description 12
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 11
- 210000000577 adipose tissue Anatomy 0.000 claims description 8
- 238000003205 genotyping method Methods 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000001605 fetal effect Effects 0.000 claims description 5
- 238000010374 somatic cell nuclear transfer Methods 0.000 claims description 3
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims 1
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 abstract description 20
- 241000282887 Suidae Species 0.000 abstract description 14
- 210000001789 adipocyte Anatomy 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 9
- 238000009395 breeding Methods 0.000 abstract description 4
- 230000001488 breeding effect Effects 0.000 abstract description 4
- 208000008589 Obesity Diseases 0.000 abstract description 3
- 235000020824 obesity Nutrition 0.000 abstract description 3
- 244000144972 livestock Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 47
- 230000010354 integration Effects 0.000 description 16
- 230000009815 adipogenic differentiation Effects 0.000 description 8
- 238000010276 construction Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 7
- 210000000229 preadipocyte Anatomy 0.000 description 7
- 108010054624 red fluorescent protein Proteins 0.000 description 7
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000000636 white adipocyte Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 239000007640 basal medium Substances 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012795 verification Methods 0.000 description 4
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 3
- 102000008579 Transposases Human genes 0.000 description 3
- 108010020764 Transposases Proteins 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 235000011449 Rosa Nutrition 0.000 description 2
- 230000002293 adipogenic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005137 deposition process Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 235000020997 lean meat Nutrition 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000004146 energy storage Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
- C12N15/877—Techniques for producing new mammalian cloned embryos
- C12N15/8778—Swine embryos
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Environmental Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of biology, and provides a pig adipose tissue development tracing system and application thereof, wherein the system comprises two vectors of px330-Rosa26 and pRosa-AdipoTracer-KI. Cells or individuals of AdipoTracer systems are integrated in the pig friendly locus Rosa26 at fixed points, and the constructed pig fat tracer system can respond to 4-hydroxy tamoxifen (4-OHT) induction, so that the development and development processes of pig fat cells are traced, the pig fat tracer system has important significance for breeding pigs and other large-scale livestock, and has important reference value for treating human obesity.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a pig adipose tissue development tracing system and application thereof.
Background
The fat has very important biological significance, can provide fatty acid and energy for living bodies, not only plays a role in energy storage, but also plays a very important role in maintenance and metabolic regulation of energy steady state. Meanwhile, fat is an indispensable substance for forming new tissues and repairing old tissues in the organism, is an important endocrine organ, and has physiological functions of protecting viscera, preserving heat of the organism and the like.
Pigs are an important economic animal and have close relation with human life. In the live pig industry, fat deposition of pigs is one of the complex economic traits, and is closely related to backfat thickness, lean meat percentage and feed conversion efficiency, and meat quality is influenced by intramuscular fat content. The genetic nature understanding of the development characteristics of pig fat and the analysis of the regulation and control mechanism of fat specific deposition at different parts are key to realizing the cooperative breeding of lean meat percentage and meat quality, and are the premise and basis for cultivating low-fat high-quality pig varieties. At present, the control mechanism of directional deposition of adipose tissues of pigs is not clear, and there is an urgent need to develop a genetic lineage tracing technology (GENETIC LINEAGE TRACING) of adipose tissues for revealing the fat deposition process of pigs.
Genetic lineage tracing technology is a method of using a specific method to label a specific cell or a specific class of cells, and the system tracks and displays the cell fate, and is used to reveal the phenomenon of self-renewal, differentiation and transdifferentiation of specific cell types in development, disease and regeneration. Currently, this technology has been widely used in model animals. Compared with mice, the construction of a genetic tracing pig system faces two difficulties, firstly, two to three transgenic mice carrying different elements are required to be bred for constructing the genetic tracing mice, and the period of constructing the pig tracing system according to the strategy is very long and is difficult to realize; secondly, the effective porcine adipocyte specific promoter has not been verified, which is easy to cause interference of non-target cell signals, has low signal-to-noise ratio and poor resolution.
Therefore, the development of a novel pig fat tracer system analyzes the fat deposition process of pigs, has important significance for pig breeding and has important reference value for treatment of human obesity.
Disclosure of Invention
The invention aims to provide a pig adipose tissue development tracing system and application thereof.
In order to achieve the aim of the invention, in a first aspect, the invention provides a pig adipose tissue development tracing system, which consists of a pig adipose tracing carrier and a targeting carrier;
The pig fat tracer vector comprises a sequence consistent with the sgRNA of a targeted pig Rosa26 gene (namely pRosa protospacer sequence, the reverse complementary sequence of which can be specifically identified by the sgRNA sequence), a CRE ERT2 element for pAdipoq expression initiation and a mTmG element for pCAG expression initiation, and the nucleotide sequences of the elements are formed by sequentially connecting SEQ ID NO. 6-8; the targeting vector is a targeting vector which comprises an sgRNA sequence of a targeted pig Rosa26 gene and expresses Cas9 protein, and the nucleotide sequence of the targeting vector is shown as SEQ ID NO. 9.
The porcine adipose tissue development tracer system of the invention can respond to 4-hydroxy tamoxifen (4-OHT) induction.
In a second aspect, the invention provides the use of the system in the tracing of porcine adipose tissue developmental lineages.
In a third aspect, the present invention provides a method of tracing a porcine adipose tissue developmental lineage, the method comprising: and co-transfecting the pig fetal fibroblasts with the pig adipose tracer vector and the targeting vector, obtaining a monoclonal cell line with a pig adipose tissue development tracer system integrated at fixed points through flow cell sorting and genotyping, and preparing a transgenic pig through a somatic cell nuclear transfer technology so as to trace the development process of adipose tissues.
Further, primers used for genotyping were as follows:
5-F: 5’-CCTCCGGGGGAGTCGGTTTA-3’，
5-R: 5’-TTTCCTCCTCTCCTGACTAC-3’；
3-F: 5’-CCGCCGCGCTTAATGCGCCG-3’，
3-R: 5’-AGGTCCAATCGCAGTGGTAG-3’。
The invention provides a pig fat tracer system (namely a pig adipose tissue development tracer system), which is used for integrating the pig fat tracer system at fixed points in a Rosa26 friendly gene locus of an isolated fibroblast fetal cell genome of a target animal, and can respond to 4-OHT induction and permanently mark mature adipocytes as green in a adipogenic differentiation process so as to trace the occurrence and development processes of the pig fat cells.
The site-directed integration can cleave the porcine Rosa 26-friendly gene site by CRISPR/Cas9, TALEN, or ZFN. The fat specific expression pRosa-AdipoTracer-KI vector (namely the pig fat tracer vector) is integrated at fixed points in the pig Rosa26 friendly gene locus by combining with a non-homologous recombination dependent fixed point integration strategy.
Further, the identification and cleavage of the pig Rosa26 friendly gene locus is carried out by CRISPR/Cas9, the CRISPR/Cas9 vector px330-Rosa26 shown in SEQ ID NO 9 has the nucleotide sequence GTGAGAGTTATCTGACCGTA from 250 th to 269 th of the 5' end as sgRNA-pRosa spacer, the corresponding specific identification region has the nucleotide sequence SEQ ID NO 5 from 1640 th to 1659 th of the 5' end as well as the nucleotide sequence SEQ ID NO 7 from 17128 th to 17147 th of the 5' end.
Further, the site-directed integration vector pRosa-AdipoTracer-KI vector sequence consists of SEQ ID NO: 6-8, wherein the combination of regulatory elements is the innovation of the invention, wherein the nucleotide sequence of SEQ ID NO:6 from the 5' end at positions 4-66 is a PiggyBac 3' inverted repeat sequence, the nucleotide sequence of SEQ ID NO:6 from the 5' end at positions 663-2264 is a pCAG sequence, the nucleotide sequence of SEQ ID NO:6 from the 5' end at positions 2366-5678 is a mTmG (LoxP-mT-LoxP-mG) sequence expressing red fluorescent protein, the nucleotide sequence of SEQ ID NO:6 from the 5' end at positions 6794-10000 and the nucleotide sequence of SEQ ID NO:7 from the 5' end at positions 10001-12284 is a fat specific promoter pAdipoq sequence, the nucleotide sequence of SEQ ID NO:7 from the 5' end at positions 12308-15229 is a Cre ERT2 sequence, the nucleotide sequence of SEQ ID NO:7 from the 5' end at positions 17050-17084 is a PiggyBac 5' inverted repeat sequence, and the nucleotide sequence of SEQ ID NO:7 from the 5' end at positions 17128 from the 5' end at positions from nucleotide sequence of 24 to 24 ac.
Further, the primers in table 1 are adopted to carry out PCR amplification on the monoclonal cells, PCR amplification products are detected, and monoclonal cells with the fragment sizes of the amplification products being the corresponding values of the fixed-point integration product sizes are selected to carry out sequencing, and the sequencing result is AdipoTracer system fixed-point integration cells with correct sequencing results.
TABLE 1 identification primer information Table
Further, fetal fibroblasts prepared according to the method and containing AdipoTracer system site-directed integration were obtained by somatic cell nuclear transfer to fat tagged pigs.
The animal of the invention is a mammal, in particular a pig, and the tissue is in particular fat.
By means of the technical scheme, the invention has at least the following advantages and beneficial effects:
The invention provides construction and application of a pig fat tracer system, which comprises two vectors, namely px330-Rosa26 and pRosa-AdipoTracer-KI. Cells or individuals of AdipoTracer systems are integrated in the pig friendly locus Rosa26 at fixed points, and the constructed pig fat tracer system can respond to 4-OHT induction, so that the development and development processes of pig fat cells are traced, the pig fat tracer system has important significance for breeding pigs and other large-scale domestic animals, and has important reference value for treating human obesity.
Drawings
FIG. 1 is a schematic diagram showing the construction and cell verification of a fluorescent tracer (AdipoTracer) system specific for mature fat in response to 4-OHT induction in accordance with a preferred embodiment of the invention; wherein A is a schematic diagram of a mature fat specific tracer system PB-AdipoTracer; b sorting tdTomato positive 3T3-L1 preadipocyte line for FACS; C4-OHT treatment differentiated 3T3-L1 preadipocytes to produce mature adipocytes that express EGFP.
FIG. 2 is a schematic representation of the design and selection of high efficiency sgRNAs targeting porcine Rosa26 sites in accordance with a preferred embodiment of the present invention.
FIG. 3 is a diagram showing the selection and identification of AdipoTracer site-directed integration of PEF monoclonal cell lines in accordance with a preferred embodiment of the present invention; wherein A is the construction flow of a AdipoTracer site-directed integrated PEF monoclonal cell line; b is the gel electrophoresis identification result of AdipoTracer-KI-1# positive monoclonal cell line PCR products; c is the Sanger sequencing result of AdipoTracer-KI-1# positive monoclonal cell line at the integration site.
FIG. 4 is a schematic illustration of the AdipoTracer system of the preferred embodiment of the present invention in the adipogenic differentiation of PEF cells; wherein A is the lipid-forming differentiation schematic diagram of a Rosa26-AdipoTracer-KI-PEF monoclonal cell line; b is the results of oil red O and fluorescence photographs of Rosa26-AdipoTracer-KI-PEF monoclonal cell line when treated with WAT inducer and 4-OHT for 15: 15 d.
Detailed Description
The invention provides a pig fat tracer system: first, a mature fat specific tracer system was constructed, comprising a Piggybac (PB) transposon plasmid (PB-AdipoTracer) containing a CRE ERT2 element whose expression is initiated by a fat specific promoter pAdipoq and a mTmG element whose expression is initiated by pCAG, and a PB transposase plasmid (Super PB), both plasmids were co-transfected into a mouse preadipocyte line 3T3-L1 for verification, and the system was found to normally respond to induction by 4-hydroxy tamoxifen (4-OHT), indicating that the system was successfully constructed.
Secondly, aiming at a first intron sequence of a friendly gene locus Rosa26 of pigs, designing effective sgRNA, and constructing a corresponding clustered regular interval short palindromic repeat sequence and a related protein 9（clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9, CRISPR/Cas9） carrier px330-Rosa26 thereof; construction of a pRosa-AdipoTracer-KI vector containing the pRosa protospacer sequence, the CRE ERT2 element for expression of fat-specific promoter pAdipoq and the mTmG element for pCAG; co-transfecting pig fetal fibroblasts (porcine embryo fibroblast, PEF) with a px330-Rosa26 vector and a pRosa26-AdipoTracer-KI vector, screening a fixed-point integrated Rosa26-AdipoTracer-KI-PEF cell line by a CRISPR/Cas9 mediated non-homologous recombination dependent fixed-point Integration (HITI) strategy, wherein the Cas9 on the px330-Rosa26 vector can not only recognize and cut a first intron sequence in a Rosa26 friendly gene locus on a PEF cell genome, but also specifically recognize and cut a pRosa protospacer sequence on a pRosa26-AdipoTracer-KI vector, thereby achieving the aim of linearizing the pRosa26-AdipoTracer-KI vector; we finally successfully screened the Rosa26-AdipoTracer-KI-PEF monoclonal cell line by flow cell sorting (Fluorescence ACTIVATING CELL Sorter, FACS) and genotyping.
Finally, adipogenic differentiation and 4-OHT treatment were performed on the Rosa26-AdipoTracer-KI-PEF monoclonal cell line obtained by screening, further verifying that AdipoTracer system was able to respond effectively to 4-OHT induction in porcine cells. Based on the above, the invention focuses on the construction of a pig fat specific tracer system and the application of the pig fat specific tracer system in analysis of development rules, cell compositions and molecular regulation mechanisms of pig fat tissues.
The invention provides an application of a pig fat tracer system in at least one of the following 1) -5):
1) Tracing in the adipogenic differentiation process of mouse preadipocytes;
2) Cleavage of the Rosa 26-friendly gene locus in the pig genome;
3) Tracing in the process of adipogenic differentiation of porcine preadipocytes;
4) Tracing during adipogenic differentiation of porcine PEF cells;
5) Preparation of fat-specific tracer gene editing pigs.
Preferably, the PB-AdipoTracer transposable vector sequence containing pAdipoq CRE ERT2 element for promoting expression and mTmG element for promoting pCAG expression is formed by sequentially connecting SEQ ID NO. 1-3.
Preferably, the PB transposase plasmid Super PB vector sequence is shown in SEQ ID NO. 4.
Preferably, the nucleotide sequence specifically recognized by sgRNA in the first intron of the Rosa26 gene locus in the pig genome is shown as SEQ ID NO. 5.
Preferably, the pRosa-AdipoTracer-KI vector containing pRosa protospacer sequence, CRE ERT2 element for pAdipoq expression promotion and mTmG element for pCAG expression promotion is formed by sequentially connecting SEQ ID NO. 6-8.
Preferably, the px330-Rosa26 vector sequence which specifically recognizes and cleaves the first intron sequence of the Rosa26 friendly gene locus in the pig genome, the pRosa protospace sequence in pRosa-AdipoTracer-KI vector is shown as SEQ ID NO. 9.
The following examples are illustrative of the invention and are not intended to limit the scope of the invention. Unless otherwise indicated, the examples are in accordance with conventional experimental conditions, such as the molecular cloning laboratory Manual of Sambrook et al (Sambrook J & Russell DW, molecular Cloning: a Laboratory Manual, 2001), or in accordance with the manufacturer's instructions.
Example 1 construction and cell verification of a fluorescent tracer (AdipoTracer) System specific for mature fat in response to 4-OHT induction
PB transposon plasmid PB-AdipoTracer (FIG. 1A, the sequences of which are sequentially connected by SEQ ID NO: 1-3) containing CRE ERT2 element whose expression is promoted by fat specific promoter pAdipoq and mTmG element whose expression is promoted by pCAG was constructed, and co-transfected with PB transposase plasmid Super PB (SEQ ID NO: 4) into 3T3-L1 mouse preadipocyte line. After long-term culture of 16 d, cells accounting for 16.9% of the total cell integration pAdipoq-Cre ERT2 -pCAG-mTmG system, tdTomato red fluorescent protein was continuously expressed (FIG. 1B). Red fluorescent-labeled 3T3-L1 preadipocytes were sorted, enriched, and simultaneously subjected to white fat (WAT) cell differentiation and 4-OHT treatment by FACS: treatment was performed with 3T3-L1 white adipocyte differentiation medium (DMEM/F12 basal medium containing 10% FBS, 1% Penicillin (PS), 20 mM HEPES, 5 μg/mL insulin, 1 μM dexamethasone, 0.5. 0.5 mM isobutyl methylxanthine, and 1 μM rosiglitazone) for 4 days. Subsequently, 3T3-L1 white adipocyte maturation medium (DMEM/F12 basal medium containing 10% FBS, 1% PS, 5 μg/mL insulin, and 1 μg/mL dexamethasone) was used for 4 days, with fresh maturation medium replaced every 2 d. 4-OHT induced group cells, wherein 4-OHT drug treatment is continuously carried out in the process of adipogenic induced differentiation, namely 1 [ mu ] M4-OHT is additionally added into white adipocyte differentiation and maturation medium. It was verified by fluorescence detection analysis whether AdipoTracer system was able to respond efficiently to 4-OHT induction in mouse cells, giving rise to a tdTomato red fluorescence to EGFP green fluorescence conversion.
The mature adipocytes can be permanently marked as green by 4-OHT induction, and the mature adipocytes which are newly grown after the induction is stopped are permanently marked as red, so that the amount of red fluorescent markers can reflect the proliferation degree of the cells, and the size change of the adipocytes marked by green fluorescent markers can reflect the hypertrophy change of the cells. Therefore, the key time law and characteristic difference of adipose tissue development can be revealed.
Fluorescence photography was performed at induction number 8 d, and it was found that induction of differentiated mature adipocyte expression enhanced green fluorescent protein (ENHANCED GREEN Fluorescent Protein, EGFP) (fig. 1C). The above results indicate that a fluorescent tracer plasmid vector specific for mature fat in response to 4-OHT induction has been successfully constructed.
Example 2 design and screening of efficient sgrnas targeting the porcine Rosa26 site
Targeting sgrnas were designed for the first intron sequence in the Rosa26 friendly locus on the pig genome using the sgRNA design and evaluation website CRISPOR (http:// crispor. Tefor. Net /), from which 3 websites were selected for validation of sgrnas (numbered sgrnas 1-3) with high editing efficiency and low off-target activity in PEF cells of pigs (fig. 2A). And respectively constructing px330-sgRNA 1-3 vectors, transfecting the vectors into PEF cells of pigs, collecting mixed cells at 48h of transfection, extracting cell DNA, and amplifying target fragments by PCR, wherein the primers are 5-F (SEQ ID NO: 10) and 3-R (SEQ ID NO: 13). Mixed cell editing efficiency was tested by Sanger sequencing and editing efficiency analysis website TIDE (https:// TIDE. Nki. Nl /). Editing efficiency analysis results found that the efficiency of px330-sgRNA3 cleavage of the pig Rosa26 friendly locus was significantly higher than that of px330-sgRNA1 and px330-sgRNA2 (fig. 2B). Thus, it is preferred that px330-sgRNA3 specifically recognizes and site-specifically cleaves the first intron sequence in the Rosa26 friendly gene locus on the pig genome, designated px330-Rosa26 vector (SEQ ID NO: 9).
Example 3 construction of AdipoTracer System site-directed integration into porcine Rosa26 site and screening and identification of PEF monoclonal cell lines
PRosa26 protospacer (GTGAGAGTTATCTGACCGTAAGG, the underlined region is NGG sequence) is designed aiming at the first intron region (SEQ ID NO: 5) of the Rosa26 friendly locus in pig gene pigs, and the sequence is constructed to a donor vector to finally form pRosa-AdipoTracer-KI (which is formed by sequentially connecting SEQ ID NO: 6-8). The vector also contains the CRE ERT2 element for pAdipoq to promote expression and the mTmG element for pCAG to promote expression.
As pRosa-AdipoTracer-KI vector also contains pRosa protospacer sequence, the sequence can be identified and cut by the specificity of px330-Rosa26 vector, thereby achieving the purpose of linearizing pRosa-AdipoTracer-KI vector.
Two vectors pRosa-AdipoTracer-KI and px330-Rosa26 were co-transfected into porcine PEF cells. Cell culture was performed by CRISPR/Cas9 mediated HITI non-homology dependent site-directed integration strategy using FACS sorting of monoclonal cells (fig. 3A). After culturing 10 d, genotyping the well-grown monoclonal cell line, including site-directed integration of the 5 'junction sequence, the 3' junction sequence, and the site-directed integration of the full-length sequence, and screening AdipoTracer positive PEF monoclonal cell line site-directed integration at Rosa26 site. Genotyping primer information is shown in Table 1.
The amplification and clone sequencing results of the PCR products show that the fixed-point integration of one chromosome (Allle 1) of the 1 # cell line is realized, the size of the amplified product at the 5 'joint is 1739bp, 1bp insertion exists, the size of the amplified product at the 3' joint is 656bp, and 6bp deletion exists (figures 3B and 3C); the other chromosome (Allele 2) was not site-specific but had a deletion of 1bp at the target site. Meanwhile, the length of the pre-amplified fragment of the full-length identification primer integrated at fixed point reaches 23197 bp, so that the pre-amplified fragment is difficult to amplify, and only a 1301bp fragment-sized band is amplified. The above results indicate that the 1 # cell line is a AdipoTracer-KI heterozygous knock-in cell line, designated as the Rosa26-AdipoTracer-KI-PEF monoclonal cell line.
Example 4 AdipoTracer verification of System in the adipogenic differentiation of PEF cells
The Rosa26-AdipoTracer-KI-PEF monoclonal cell line expressed red fluorescence when untreated. It was subjected to simultaneous WAT inducer and 4-OHT treatment: 1 [ mu ] M4-OHT drug was added to white adipocyte differentiation medium (DMEM basal medium containing 10% FBS, 1% PS, 20mM HEPES, 5 [ mu ] g/mL insulin, 17 [ mu ] M pantothenic acid, 33 [ mu ] M biotin, 1 [ mu ] M dexamethasone, 0.25 mM isobutyl methylxanthine and 1 [ mu ] M rosiglitazone) and treated for 5 days. Subsequently, 1 [ mu ] M4-OHT drug was added to white adipocyte maturation medium (DMEM basal medium containing 10% FBS, 1% PS, 5 [ mu ] g/mL insulin, 17 [ mu ] M pantothenic acid, 33 [ mu ] M biotin and 1 [ mu ] M dexamethasone) for 10 days, with fresh maturation medium replaced every 3 d. Oil red O staining and fluorescence photography were performed at induction 15d (fig. 4A). As a result, it was found that this cell line was able to differentiate into a large amount of oil red O-stained mature adipocytes at the time of adipogenic induction for 15d (FIG. 4B). In the adipogenic differentiation process, the mature adipocytes generated by adding 4-OHT treatment can be converted from tdTomato red fluorescence to GFP green fluorescence; whereas mature adipocytes not subjected to 4-OHT treatment expressed only red fluorescence (fig. 4B).
The invention successfully induces and differentiates PEF cells into mature adipocytes, and further verifies that AdipoTracer systems can effectively respond to 4-OHT induction in pig cells, thereby laying a foundation for preparing AdipoTracer fixed-point integrated pigs by subsequent combined body nuclear transfer (SCNT) and embryo transfer technology.
Sequence description:
1. The PB-Adipotracer (PB-pCAG-mTmG-pAdipoq-Cre ERT2) vector sequence is formed by sequentially connecting SEQ ID NO 1-3, wherein the nucleotide sequence of SEQ ID NO 1 from the 5' -end at positions 4-66 is a PiggyBac 3' inverted repeat sequence, the nucleotide sequence of SEQ ID NO 1 from the 5' -end at positions 663-2264 is a pCAG sequence, the nucleotide sequence of SEQ ID NO 1 from the 5' -end at positions 2366-5678 is a mTmG (LoxP-mT-LoxP-mG) sequence for expressing red fluorescent protein, the nucleotide sequence of SEQ ID NO 1 from the 5' -end at positions 6794-10000 and the nucleotide sequence of SEQ ID NO 2 from the 5' -end at positions 10001-12284 is a fat specific promoter pAdipoq sequence, the nucleotide sequence of SEQ ID NO 2 from the 5' -end at positions 12308-15229 is a Cre ERT2 sequence, and the nucleotide sequence of SEQ ID NO 2 from the 5' -end at positions 50-84 is a PiggyBac 5' inverted repeat sequence.
2. Super PB (pCAG-PBase) vector sequence SEQ ID NO. 4, wherein the base sequence of 4-1670 is pCAG sequence, and the nucleotide sequence of 1735-3519 is PBase sequence.
3. In the first intron of the Rosa26 gene locus in the pig genome, the nucleotide sequence specifically recognized by sgRNA is SEQ ID NO. 5, wherein nucleotide sequences 1-124 are exon 1 regions, nucleotide sequences 125-2000 are partial intron 1 sequences, and nucleotide sequences 1640-1659 are regions specifically recognized by sgRNA.
4. PRosa26-AdipoTracer-KI (PB-pCAG-mTmG-pAdipoq-Cre ERT2- pRosa26 protospacer) vector sequence consisting of SEQ ID NO: 6-8, wherein the nucleotide sequence of SEQ ID NO:6 from 5 'end 4-66 is piggyBac 3' inverted repeat sequence, the nucleotide sequence of SEQ ID NO:6 from 5 'end 663-2264 is pCAG sequence, the nucleotide sequence of SEQ ID NO:6 from 5' end 2366-5678 is mTmG (LoxP-mT-LoxP-mG) expressing red fluorescent protein, the nucleotide sequence of SEQ ID NO:6 from 5 'end 6794-10000 and SEQ ID NO:7 from 5' end 10001-12284 is fat specific promoter pAdipoq sequence, the nucleotide sequence of SEQ ID NO:7 from 5 'end 12308-15229 is Creet 2 sequence, the nucleotide sequence of SEQ ID NO:7 from 5' end 17050-17084 is PickyBac 5 'inverted repeat sequence, and the nucleotide sequence of SEQ ID NO:7 from 5' end 17128-6250 is proto 42 procter sequence.
5. The vector sequence of px330-pRosa is SEQ ID NO. 9, wherein the nucleotide sequence at 250-269 is the sgRNA-pRosa spacer sequence.
6. The 5-F/5-R primer sequence is shown in SEQ ID NO. 10-11, and the 3-F/3-R primer sequence is shown in SEQ ID NO. 12-13.
While the invention has been described in detail in the foregoing general description and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that modifications and improvements can be made thereto. Accordingly, such modifications or improvements may be made without departing from the spirit of the invention and are intended to be within the scope of the invention as claimed.
Claims (5)
1. The pig adipose tissue development tracing system is characterized by comprising a pig adipose tracing carrier and a targeting carrier;
The pig fat tracer vector comprises a sequence consistent with sgRNA of a targeted pig Rosa26 gene, a CRE ERT2 element for pAdipoq to start expression and a mTmG element for pCAG to start expression, and the nucleotide sequences of the pig fat tracer vector are formed by sequentially connecting SEQ ID NO. 6-8;
The targeting vector is a targeting vector which comprises an sgRNA sequence of a targeted pig Rosa26 gene and expresses Cas9 protein, and the nucleotide sequence of the targeting vector is shown as SEQ ID NO. 9.
2. The system of claim 1, wherein the system is responsive to induction by 4-hydroxy tamoxifen.
3. Use of the system of claim 1 or 2 for tracing porcine adipose tissue developmental lineages.
4. A method of tracing a porcine adipose tissue developmental lineage, the method comprising: co-transfecting the pig fetal fibroblasts with the pig adipose tracer vector and the targeting vector according to claim 1 or 2, obtaining a monoclonal cell line with a pig adipose tissue development tracer system integrated at fixed points through flow cell sorting and genotyping, and preparing a transgenic pig through a somatic cell nuclear transfer technology to trace the development progress of adipose tissue.
5. The method according to claim 4, wherein the primers used for genotyping are as follows:
5-F: 5’-CCTCCGGGGGAGTCGGTTTA-3’，
5-R: 5’-TTTCCTCCTCTCCTGACTAC-3’；
3-F: 5’-CCGCCGCGCTTAATGCGCCG-3’，
3-R: 5’-AGGTCCAATCGCAGTGGTAG-3’。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410497313.6A CN118086394B (en) | 2024-04-24 | 2024-04-24 | Pig adipose tissue development tracing system and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410497313.6A CN118086394B (en) | 2024-04-24 | 2024-04-24 | Pig adipose tissue development tracing system and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118086394A true CN118086394A (en) | 2024-05-28 |
| CN118086394B CN118086394B (en) | 2024-07-12 |
Family
ID=91157671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410497313.6A Active CN118086394B (en) | 2024-04-24 | 2024-04-24 | Pig adipose tissue development tracing system and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118086394B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106916820A (en) * | 2017-05-16 | 2017-07-04 | 吉林大学 | SgRNA and its application of porcine ROSA 26 gene can effectively be edited |
| US20190032155A1 (en) * | 2017-07-31 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Cas-ready mouse embryonic stem cells and mice and uses thereof |
| CN113943749A (en) * | 2021-09-24 | 2022-01-18 | 河南大学 | Method for improving homologous recombination efficiency based on CRISPR gene editing system |
| CN114761035A (en) * | 2019-06-17 | 2022-07-15 | 西达-赛奈医疗中心 | Systems and methods for dual recombinant enzyme mediated cassette exchange (dRMCE) in vivo and disease models therefor |
| CN116103342A (en) * | 2022-12-14 | 2023-05-12 | 中国农业大学 | Pedigree tracing method for sheep early embryo development based on CRISPR-Cas9 system and PB transposon system |
-
2024
- 2024-04-24 CN CN202410497313.6A patent/CN118086394B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106916820A (en) * | 2017-05-16 | 2017-07-04 | 吉林大学 | SgRNA and its application of porcine ROSA 26 gene can effectively be edited |
| US20190032155A1 (en) * | 2017-07-31 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Cas-ready mouse embryonic stem cells and mice and uses thereof |
| CN114761035A (en) * | 2019-06-17 | 2022-07-15 | 西达-赛奈医疗中心 | Systems and methods for dual recombinant enzyme mediated cassette exchange (dRMCE) in vivo and disease models therefor |
| CN113943749A (en) * | 2021-09-24 | 2022-01-18 | 河南大学 | Method for improving homologous recombination efficiency based on CRISPR gene editing system |
| CN116103342A (en) * | 2022-12-14 | 2023-05-12 | 中国农业大学 | Pedigree tracing method for sheep early embryo development based on CRISPR-Cas9 system and PB transposon system |
Non-Patent Citations (3)
| Title |
|---|
| EWA BIELCZYK-MACZYŃSKA等: "Loss of adipocyte identity through synergistic repression of PPARγ by TGF-β and mechanical stress", SCIENTIFIC REPORTS, 11 April 2019 (2019-04-11), pages 1 - 31 * |
| PETER A. TENNANT等: "Fluorescent in vivo editing reporter (FIVER): A novel multispectral reporter of in vivo genome editing", BIORXIV, 14 July 2020 (2020-07-14), pages 1 - 39 * |
| 赵旭东等: "动物转基因高效表达策略研究进展", 生物技术通报, vol. 36, no. 3, 31 December 2020 (2020-12-31), pages 45 - 53 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118086394B (en) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104745626B (en) | A kind of fast construction method of conditional gene knockout animal model and application | |
| Sakurai et al. | A single blastocyst assay optimized for detecting CRISPR/Cas9 system-induced indel mutations in mice | |
| CN106916820B (en) | SgRNA and its application of porcine ROSA 26 gene can effectively be edited | |
| CN104531705A (en) | Method for knocking off animal myostatin gene by using CRISPR-Cas9 system | |
| CN107974466A (en) | A kind of sturgeon CRISPR/Cas9 gene editing methods | |
| CN106244557A (en) | Rite-directed mutagenesis ApoE gene and the method for LDLR gene | |
| CN104531704A (en) | Method for knocking off animal FGF5 gene by using CRISPR-Cas9 system | |
| CN111019971A (en) | Construction method of mouse model for conditionally overexpressing HPV E6 gene at ROSA26 site | |
| CN109112159A (en) | Based on the Cas9 site-directed integration FABP4 gene mediated and MSTN point mutation targeting vector and recombinant cell | |
| CN110257435B (en) | Construction method and application of PROM1-KO mouse model | |
| CN105925579B (en) | The sgRNA and its coding DNA of a pair of of specific recognition pig IGF2 gene introns and application | |
| CN106086031A (en) | Pig flesh chalone gene editing site and application thereof | |
| CN111363743B (en) | SCD gene knockout pig fetus fibroblast line and construction method thereof | |
| CN106754949B (en) | Pig flesh chalone gene editing site 864-883 and its application | |
| CN103952405A (en) | Goat MSTN (myostatin) gene fixed-point modification system and application thereof | |
| CN118086394B (en) | Pig adipose tissue development tracing system and application | |
| CN109652459A (en) | A kind of honeybee gene editing method and editor's material based on CRISPR/Cas9 | |
| CN111549070B (en) | Method for editing X chromosome multicopy gene to realize animal sex control | |
| CN104894255B (en) | A kind of method and its application detecting inefficient genome editor based on polyacrylamide gel electrophoresis | |
| CN105950622B (en) | The crRNA of specific recognition GS gene and its application | |
| CN109679998B (en) | Vector for site-specific mutagenesis of MSTN (myostatin) and simultaneous site-specific integration of PPAR (peroxisome proliferator activated receptor) gamma | |
| WO2024069186A1 (en) | Genetically modified cells | |
| CN111893119A (en) | Method for obtaining SCD1 gene editing goat embryo by CRISPR/Cas9 system and microinjection | |
| CN106244556A (en) | The method of rite-directed mutagenesis ApoE gene | |
| CN104726495B (en) | A kind of gene targeting based on TALEN mediations knocks out the carrier and recombinant cell of goat BLG |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |